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Introduction
What is Schizophrenia (SCZ)?
• Chronic & debilitating neurobehavioral disorder
• Affects estimated 21 million people worldwide (WHO Statistics Sheet, 2018)
• Age at onset observed in adolescence or early adulthood
• Diagnosis based on clinical observation or self-reporting (Gejman et al., 2010)
• Costs U.S. approx. $62 billion annually for medications & other 
therapeutic expenses
Current Treatment 
• Antipsychotic Medications 
• Typical – dopamine D2 antagonists (e. g. Haloperidol)
• Attempts to treat associated positive symptoms
• Atypical – dopamine D2 antagonists; act on histamine, 
norepinephrine, & serotonin (e. g. Clozapine, Olanzapine, & 
Risperidone)
• Attempts to treat associated positive & negative symptoms
• Psychosocial Interventions
• Individual & family therapy, social skills training, and vocational 
rehabilitation 
Problems with Current Treatment
• Typical antipsychotic drugs (FGA)
• Not designed to treat (-) symptoms
• Potent extrapyramidal motor side effects
• Atypical antipsychotic drugs (SGA)
• Dose-dependent side effects (Solmi et al., 2017)
Weight gain, insulin resistance/diabetes, cognitive impairment, 
agranulocytosis, seizures, pneumonia, myocarditis, & 
hypersalivation.




• SCZ patients shown to have increased 
inflammation in CNS (Howes & McCutcheon, 2017; Van 
Kesteren et al., 2017)
Image adapted from Harvard Health Publishing 
PFC
Image adapted from Bloomfield et al., 2016
Tumor Necrosis Factor-alpha (TNFα)
• Pro-inflammatory cytokine
• Implicated in some autoimmune diseases (ex. RA)
• Influence state of CNS defense cells, called microglia
Image from MEDBULLETS:STEP 1
Microglial Cells
• Primary immune cells of the CNS & scan local environment for cellular stress 
(Nimmerjahn et al., 2005)
• Normally exist as anti-inflammatory, neuroprotective agents (M2 state)
• Upon activation by TNFα secretion, switch to M1 state, which is pro-inflammatory &
neurotoxic
• Activated M1 microglia leads to overexpression of pro-inflammatory cytokines (ex. 
TNFα) & ROS, resulting in synaptic loss & neuronal death (Howes & McCutcheon, 2017)
P2D Bioscience, Inc. 
TNFα Modulator Development
• Isoindoline-derived compounds
• PD2024 & PD340
• Small, anti-TNF molecules
• Destabilizes TNFα mRNA
• Decreases TNFα protein release & secretion 
• Centrally-acting, anti-neuroinflammatory properties
• Safe & well tolerated in small (rats) and large (dogs) animals
PD2024
Mw = 179.0 g/mol
TNFα IC50 = 3 μM
Polyinosinic:polycytidylic Acid (Poly I:C)
• Immunostimulant
• Interaction with TLR3
• Synthetic dsRNA (virus-like)
• Activates innate immune system
• Mimics neonatal infection in humans
Image from: https://www.biomol.com/product_Polyinosinic-polycytidylic-Acid-potassium-salt.html?aRelated=Cay16881
Poly I:C Rodent Model of SCZ
• Behavioral deficits/neuropathology consistent with SCZ
• Sensorimotor gating  
• Cognitive 
• Dopamine hyperfunction
• Structural abnormalities (cortical volume reduction in PFC & HPC) 
(Meyer, 2014)
• Symptoms emerge in offspring, reflects delayed onset as seen 
in humans
• Clozapine & Risperidone alleviate deficits in neonatally 
treated poly I:C rats
Hypotheses
1. Treatment with Poly I:C will increase TNFα protein levels similar to 
the neuroinflammatory response for individuals diagnosed with 
schizophrenia
2. Novel TNFα modulators will alleviate sensorimotor gating deficits
of the rodent Poly I:C model 
3. Novel TNFα modulators will reduce associated neuroinflammation
via a decrease in microglial cell activation levels in the HPC and 
PFC, two brain areas that mediate sensorimotor gating
Experimental Design
Study Design: Experiment 1 – TNFα Protein Levels
• A total of 17 male Sprague-Dawley pups IP injected with either Poly 
I:C (2 mg/kg) or saline (0.9% NaCl) from P5-7
• Sacrificed at P30 (in accordance with Exp. 2 & 3 dietary manipulation)
• PFC & HPC dissected away
• Tissue subjected to TNFα ELISA kit (Biomatik, Inc.; Wilmington, 
DE)
• Protein detection via colorimetric detection (450 nm)
Study Design: Experiment 2 – PD2024
Grouping & Conditions
• SD pups divided equally into 4 groups
(Poly I:C/Control, Poly I:C/PD2024, Saline/Control, Saline/PD2024)
• Poly I:C groups IP injected with Poly I:C (2 mg/kg) from P5-7
• Saline groups IP injected with saline (0.9% NaCl) from P5-7
• All animals weaned at P21, dietary manipulation began at P30
• PD2024 groups received PD2024 until P67
• Control groups received a normal diet until P67
Study Design: Experiment 3 – PD340
Grouping & Conditions
• SD pups divided equally into 6 groups
(Poly I:C/Control, Poly I:C/PD340 – 10 mg/kg, Poly I:C/PD340 – 30 mg/kg, 
Saline/Control, Saline/PD340 – 10 mg/kg, Saline/PD340 – 30 mg/kg)
• Poly I:C groups IP injected with Poly I:C (2 mg/kg) from P5-7
• Saline groups IP injected with saline (0.9% NaCl) from P5-7
• All animals weaned at P21, dietary manipulation began at P30
• PD340 groups received PD340 (10 mg/kg or 30 mg/kg) until P67
• Control groups received a normal diet until P67
Study Design: Experiments 2 & 3
Prepulse Inhibition (PPI)
• Behaviorally tested on PPI
• During adolescence (P44-46) and adulthood (P60-66)
Sacrifice & Immunohistochemistry (IHC)
• Sacrificed at P67, PFC & HPC dissected away, subjected to IHC
• IHC examined microglial cell activation using the Iba1-GFP conjugated 
antibody system
Prepulse Inhibition (PPI)





Detection technique, selectively 
identifies protein(s) in cells
Image from Exp. 3 
Results
Figure 1. TNFα Protein Levels Following Saline or 
Poly I:C Administration Between P33-35.
Figure 2. Experiment 2: PPI Performance in 
Adolescents and Adults.
Figure 3. Experiment 2: 
Microglial Cell 
Activation in the PFC 
and HPC.
Figure 4. Experiment 2: 
Representative Images 
of Iba1-GFP Labeled 
Microglia Cells in the 
PFC.
Poly I:C/Control Poly I:C/PD2024
Saline/PD2024Saline/Control
Figure 5. Experiment 3: PPI Performance for 
Adolescents and Adults.
Figure 6. Experiment 3: Microglial Cell 
Activation in the PFC and HPC.
Conclusions & Future 
Directions
Conclusions
• Neonatal Poly I:C resulted in behavioral deficits in adolescence & 
adulthood, consistent with clinical observation & diagnosis of SCZ.
• Two novel TNF-alpha modulators (PD2024 & PD340) alleviated
sensorimotor gating deficits in adolescence and adulthood.
• Decreased microglial cell activation known to mediate sensorimotor gating
Future Work & Directions
• PD2024 and PD340 adjunctively used with antipsychotic drugs in the 
Poly I:C and other rodent models of SCZ. 
Acknowledgements
Thesis Committee
Dr. Russell Brown (Chair)












David Moore (GPSA Advisor)
GPSA membership
School of Graduate Studies
Dr. Sharon McGee 




Bloomfield P S, Selveraj S, Veronese M, Rizzo G, Bertoldo A, Owen D R et al. (2016). “Microglial Activity in People at Ultra High Risk of Psychosis and Schizophrenia: An (11C) PBR28 PET Brain Imaging Study.” The American Journal of 
Psychiatry 173, Image.
Brymer K J, Romay-Tallon R, Allen J, Caruncho H J, Kalynchuk L E (2019). “Exploring the Potential Antidepressant Mechanisms of TNFα Antagonists.” Frontiers in Neuroscience 13:98. 
Egerton A, Brugger S, Raffin M et al. (2012). “Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia.” Neuropsychopharmacology 37: 2515-2521.
Gabbita S P, Johnson M F, Kobritz N, Eslami P, Poteshkina A, Varadarajan S et al. (2015). “Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model.” PLoS
One 10: e0137305.
Garrett M, Silva R (2003). “Auditory Hallucinations, Source Monitoring, and the Belief that “Voices” are Real.” Schizophrenia Bulletin 29: 445-457.
Gejman P V, Sanders A R, Duan J (2010). “The Role of Genetics in the Etiology of Schizophrenia.” Psychiatric Clinics of North America 33(1): 35-66.
Giovanoli S, Engler H, Engler A, Richetto J, Feldon J, Riva M A et al. (2016). “Preventive Effects of Minocycline in a Neurodevelopmental Two-Hit Model with Relevance to Schizophrenia.” Translational Psychiatry 6: e772.
Harvard Mental Health Letter (2011). “How Addiction Hijacks the Brain.” Harvard Health Publishing Harvard Medical School, Image. 
Howes O D, Kapur S (2009). “The Dopamine Hypothesis of Schizophrenia: Version III — The Final Common Pathway.” Schizophrenia Bulletin 35: 549-556.
Howes O D, McCutcheon R (2017). “Inflammation and the Neural Diathesis-Stress Hypothesis of Schizophrenia: A Reconceptualization.” Translational Psychiatry 7: 1-11.
Johnson K M, Jones S M (1990). “Neuropharmacology of Phencyclidine: Basic Mechanisms and Therapeutic Potential.” Annual Review of Pharmacology and Toxicology 30: 707-750.
Kusumi I, Boku S, Takahashi Y (2014). “Psychopharmacology of Atypical Antipsychotic Drugs: From the Receptor Binding Profile to Neuroprotection and Neurogenesis.” Psychiatry and Clinical Neurosciences 69(5): 243-258
Lavretsky H (2008). “Chapter 1: History of Schizophrenia as a Psychiatric Disorder.” Clinical Handbook of Schizophrenia Guilford Publications: 3-12. 
McCusker R H, Kelley K W (2013). “Immune-Neural Connections: How the Immune System’s Response to Infectious Agents Influences Behavior.” Journal of Experimental Biology 216(Pt 1): 84-98.
Meyer U (2014). “Prenatal Poly(I:C) Exposure and Other Developmental Immune Activation Models in Rodent Systems.” Biological Psychiatry 75: 307-315
Miller B J, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011). “Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects.” Biological Psychiatry 70: 663-671.
Nimmerjahn A, Kirchhoff F, Helmchen F (2005). “Resting Microglial Cells are Highly Dynamic Surveillants of Brain Parenchyma In Vivo.” Science 308(5726): 1314-1318.
Perry V H (1998). “A Revised View of the Central Nervous System Microenvironment and Major Histocompatibility Complex Class II Antigen Presentation.” Journal of Neuroimmunology 90: 113-121.
Ransohoff R M (2016). “How Neuroinflammation Contributes to Neurodegeneration.” Science 353(6301): 777-783.
Schroeter M, Dennin M A, Walberer M, Backes H, Neumaier B, Fink G R et al. (2009). “Neuroinflammation Extends Brain Tissue at Risk to Vital Peri-Infarct Tissue: A Double Tracer [11C]PK11195- and [18F]FDG-PET Study.” Journal of Cerebral 
Blood Flow Metabolism 29(6): 1216-1225.
Seeman P, Chau-Wong M, Tedesco J, Wong K (1975). “Brain Receptors for Antipsychotic Drugs and Dopamine: Direct Binding Assays.” Proceedings of the National Academy of Sciences of the United States of America 72(11): 4376-4380.
Seeman M V, Seeman P (2014). “Is Schizophrenia a Dopamine Supersensitivity Psychotic Reaction?” Progress in Neuropsychopharmacology and Biological Psychiatry 48: 155-160. 
Solmi M, Veronese M, Thapa N, Facchini S, Stubbs B, Fornaro M, Carvalho A F, Correll C V (2017). “Systemic Review and Meta-Analysis of the Efficacy and Safety of Minocycline in Schizophrenia.” CNS Spectrums 22(5): 415-426.
Stone J M, Morrison P D, Pilowsky L S (2007). “Glutamate and Dopamine Dysregulation in Schizophrenia--A Synthesis and Selective Review.” Journal of Psychopharmacology 21: 440-452.
Van Kesteren C F M G, Gremmels H, de Witte L D, Hol E M, Van Gool A R, Falkai P G et al. (2017). “Immune Involvement in the Pathogenesis of Schizophrenia: A Meta-Analysis on Postmortem Brain Studies.” Translational Psychiatry 7: e1075.
Xiang Y Q, Zheng W, Wang S B, Yang X H, Cai D B, Ng C H, Unguari G S, Kelly D L, Xu W Y, Xiang Y J (2017). “Adjunctive Minocycline for Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.” European Neuropsychopharmacology
27(1): 8-18.
Zhang J M, An J A (2009). “Cytokines, Inflammation and Pain.” International Anesthesiology Clinics 45(2): 27-37.
Zhu F, Zheng Y, Liu Y, Zhang X, Zhao J (2014). “Minocycline Alleviates Behavioral Deficits and Inhibits Microglial Activation in the Offspring of Pregnant Mice After Administration of Polyribosinic-Polyribocytidilic Acid.” Psychiatry Research
219(3): 680-686.
Online 
Donaldson L (2018). “Winning the War on Inflammation.” https://psoriatic-arthritis.com/living/winning-war-inflammation/. Visited 03.17.2019.
Mandal A (2019). “What are Cytokines?” https://www.news-medical.net/health/What-are-Cytokines.aspx. Visited 03.17.2019.
World Health Organization (2018). “Schizophrenia.” https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Visited 02.02.2019.
https://step1.medbullets.com/msk/112059/tnf-alpha-inhibitors. Visited 03.17.2019.
https://www.biolegend.com/media_assets/neuroinflammation/microglia_activation.jpg. Visited 03.17.2019.
https://www.ncbi.nlm.nih.gov/books/NBK92434/figure/immunometh.F1/. Visited 03.17.2019.
https://en.wikipedia.org/wiki/Prepulse_inhibition#/media/File:Prepulse_Inhibition_schematically.png. Visited 03.17.2019.
https://reliawire.com/dopamine/. Visited 03.23.2019.
http://www.priory.com/homol/insulin.htm. Visited 03.23.2019.
https://www.biomol.com/product_Polyinosinic-polycytidylic-Acid-potassium-salt.html?aRelated=Cay16881. Visited 03.23.2019.
https://www.semanticscholar.org/paper/PREPULSE-INHIBITION-OF-THE-ACOUSTIC-STARTLE-REFLEX/d2f991a81ab1873445dde6bcea35b6bde13b95c3/figure/0. Visited 03.23.2019.
http://www.nrlc-group.net/procedures-and-facilities/psychophysiology. Visited 03.23.2019.
Questions?
